FDA approves FASLODEX 500mg dose for metastatic breast cancer in postmenopausal women

[News]

AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved the 500mg dose of FASLODEX® (fulvestrant) Injection, replacing the previously approved monthly dose of 250mg, for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.

More... (http://www.news-medical.net/news/20100913/FDA-approves-FASLODEX-500mg-dose-for-metastatic-breast-cancer-in-postmenopausal-women.aspx)